T. Rowe Price Associates, Inc. acquired an 11.7% stake in 10x Genomics, Inc.
The institutional investor now beneficially owns 14,044,020 Class A common shares. A Schedule 13G filing with the SEC confirmed the transaction.
Stifel reiterated its Buy rating on the life science technology firm. Analysts identified the upcoming Atera instrument as a key growth driver. Stifel expects new spatial biology software to accelerate market expansion. The Atera platform will play a central role in future scaling.
10x Genomics stock surged 350% over the past year.